Navigation Links
U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction

BURLINGTON, Mass., Nov. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through examination of U.S. patient-level claims data, total patient share of platform injectable disease-modifying therapies (DMTs) among recently treated multiple sclerosis (MS) patients declined over four quarters of data collection ending June 30, 2013, with a steeper drop observed in Q2 2013, coinciding with the launch of Biogen Idec's Tecfidera. Quarterly analysis shows that injectable DMTs, namely the interferon betas and Teva's Copaxone, captured a combined 70 percent patient share among recently treated patients in Q2 2013 compared with 80 percent one year earlier. Meanwhile, during the drug's first three months on the market, Tecfidera captured a sizable patient share in this population, approaching the level of Novartis's first-to-market oral DMT Gilenya in this same quarter. These data likely reflect both pent up patient demand for Tecfidera and prescribers' positive opinions of the product's clinical profile compared with other DMTs.

However, the Treatment Algorithms in Multiple Sclerosis report also finds that platform injectables continued to capture a commanding 84 percent of first-line patient share among MS DMTs. Copaxone and Biogen Idec's Avonex were most often prescribed among newly diagnosed MS patients, together capturing over 60 percent of first-line patient share in this population, likely owing to their established advantages in tolerability and delivery, respectively. Thanks to physician comfort and a positive long-term safety record, injectable DMTs maintained a dominant first-line position despite the availability of newer oral alternatives—Gilenya, Tecfidera and Genzyme's Aubagio—which combined to capture only just 6 percent of first-line patient share, driven mostly by Gilenya.

"U.S. claims data confirm that time-tested injectables remain a core component of MS treatment, overall and in treatment-naive patients, likely due in part to neurologists' conservative adoption of new agents," said Decision Resources Senior Director Jonathan W. Searles. "That said, with oral DMTs capturing nearly 18 percent total patient share in the second quarter among patients in our sample who were recently treated, and with the use of Tecfidera surging, we anticipate continued steady losses among current mainstays over the near-term."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of ViroPharma, Inc. - VPHM
2. Omnicare (NYSE: OCR) Agrees to Pay United States $120 Million to Settle False Claims Act Suit Alleging Kickbacks
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
4. Gene By Gene Rejects BRCA1/2 Patent Infringement Claims by Myriad and Joins Ambry Genetics to Sue Myriad for Violating Federal Antitrust Laws
5. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
7. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
8. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
9. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
11. Argus Announces Next Generation Pharmacy Claims Processing Solution
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... Ohio , Dec. 1, 2015 ... to its GeneSight® Psychotropic test giving healthcare providers an ... medication decisions for patients suffering from depression, anxiety, ... other behavioral health conditions. i ... --> With the addition of two ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first ... Annual Meeting from November 29 to December 4, 2015. , MED-TAB is ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare ... management and population health arenas, is pleased to announce that VIP Care Services, ... has successfully implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic ...
Breaking Medicine News(10 mins):